Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
322results about How to "Lower immune response" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
PD-1 binding proteins
ActiveUS8168757B2Regulating T cell responsesImprove immunityAntibody mimetics/scaffoldsAntibody ingredientsHost immunitySignalling pathways
The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC
Device and method for attenuating an immune response
ActiveUS20050075701A1Good flexibilityMore levelsSpinal electrodesImplantable neurostimulatorsNervous systemNeuron
Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.
Owner:MEDTRONIC INC
Device and method for inhibiting release of pro-inflammatory mediator
InactiveUS20050075702A1Great flexibilityGreat specificitySpinal electrodesArtificial respirationNervous systemDrug
Stimulation of one or more neurons of the sympathetic nervous system, including the splenic nerve, to attenuate an immune response, including an inflammatory immune response, is discussed. Devices and systems to stimulate the sympathetic nervous system to attenuate an immune response are also discussed. Devices discussed include pulse generators and drug pumps. Systems are described as optionally having one or more sensors and operator instructions. In specific examples, stimulation of the splenic nerve of pigs with a pulse generator is shown to be safe and effective in attenuating a lipopolysaccharide-induced immune response.
Owner:MEDTRONIC INC
Pd-1 binding proteins
ActiveUS20110008369A1Enhance host anti-microbial immunityImprove immunityAntibody mimetics/scaffoldsImmunoglobulins against animals/humansPD-L1Host immunity
The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.
Owner:MERCK SHARP & DOHME LLC
Device and method for attenuating an immune response
ActiveUS7418292B2Good flexibilityMore levelsSpinal electrodesImplantable neurostimulatorsNervous systemImmunity response
Owner:MEDTRONIC INC
Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
InactiveUS6875430B2Ameliorate a response by the immune systemPrevent and reduce T cell responseBiocideMammal material medical ingredientsGraft versus host disease inductionGraft-versus-host disease
A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the transplant. The mesenchymal stem cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with mesenchymal stem cells.
Owner:MESOBLAST INT
Device and method for inhibiting release of pro-inflammatory mediator
ActiveUS20060287678A1Good flexibilityMore levelsSpinal electrodesArtificial respirationNervous systemNeuron
Owner:MEDTRONIC INC
Modified RNA with decreased immunostimulatory properties
ActiveUS20160235864A1Reduce innate immune responseIncrease mRNA levelsOrganic active ingredientsPeptide/protein ingredientsVaccine ImmunogenicityRNA
The present invention provides a method for providing modified mRNAs of reduced immunogenicity and / or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
Owner:CUREVAC SE
Method to reduce inflammatory response in transplanted tissue
InactiveUS20050182018A1Inhibit inflammationLower immune responseBiocideSugar derivativesPandrug resistant bacteriaDisease cause
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
InactiveUS20050079174A1Reduce inflammationReduce immune responseNervous disorderBiological material analysisImmunotherapyB cell
Methods are provided for reducing a pro-multiple sclerosis immune response by administering to an individual a composition comprising an affinity ligand which binds to B cell determinant, and which is administered in an amount effective to reduce B cells.
Owner:BIOCRYSTAL LTD
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
ActiveUS20160237134A1Low immunogenicityEnhance protein expressionDepsipeptidesOxidoreductasesBiotechnologyUracil
The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
Owner:MODERNATX INC
Regulatory t cells and methods of making and using same
InactiveUS20090136470A1Inhibiting IL-6-driven induction of Th-1Adjust balanceBiocideSenses disorderRegulatory T cellPeroxisome
Methods of stimulating or increasing differentiation to regulatory T cells, cultures of regulatory T cells and methods of reducing or decreasing an immune response, inflammation or an inflammatory response, among other things, are provided. Methods include, among other things, contacting blood cells or T cells with an amount of TGF-beta or a TGF-beta analogue and a retinoic acid receptor agonist, or an amount of a retinoid X receptor (RXR) or peroxisome proliferator activated receptor-gamma (PPARgamma) agonist, sufficient to stimulate or increase differentiation to regulatory T cells. Cultures of regulatory T cells include T cells that express a marker associated with regulatory T cells, such as cultures in which regulatory T cells represent, for example, 30% or more of the total number of cells in the culture.
Owner:LA JOLLA INST FOR ALLERGY & IMMUNOLOGY
Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion.
Owner:PLURISTEAM LTD
Method for delivering interferons to the intradermal compartment
InactiveUS20050181033A1Increase uptakeShorter TmaxPeptide/protein ingredientsMicroneedlesPharmaceutical drugEfficacy
The present invention relates to methods and devices for intradermal delivery of substances, preferably therapeutic substances by targeting the substance to the intradermal compartment of a subject's skin. Substances delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods including intramuscular, and subcutaneous delivery. The present invention provides benefits and improvements over conventional drug delivery methods including but not limited to, improved pharmacokinetics and bioavailability.
Owner:BECTON DICKINSON & CO
Use of Serum Albumin Binding Peptides Conjugates for the Preparation of a Medicament
ActiveUS20080187517A1Avoid problemsLower immune responseFactor VIIPeptide/protein ingredientsDrugAlbumin
A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal.
Owner:AFFIBODY TECH AB
Method for delivering interferons to the intradermal compartment
InactiveUS20050008683A1Increase uptakeShorter TmaxAmpoule syringesJet injection syringesBioavailabilityTissue skin
The present invention relates to methods and devices for intradermal delivery of substances, preferably therapeutic substances by targeting the substance to the intradermal compartment of a subject's skin. Substances delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods including intramuscular, and subcutaneous delivery. The present invention provides benefits and improvements over conventional drug delivery methods including but not limited to, improved pharmacokinetics and bioavailability.
Owner:BECTON DICKINSON & CO
Modified enzymes having polymer conjugates
InactiveUS6623950B1Low immunogenicityReduce allergiesOrganic detergent compounding agentsBacteriaVaccine ImmunogenicityEnzyme
The present invention relates to polypeptide-polymer conjugates having added and / or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure, a method for preparing polypeptide-polymer conjugates of the invention, the use of said conjugates for reducing the immunogenicity and allergenicity and compositions comprising said conjugate.
Owner:NOVOZYMES AS
Method for ice-free cryopreservation of tissue
ActiveUS20100216110A1Preserve extracellular matrix integrityImprove long term functionDead animal preservationDisinfectantsBiomedical engineeringGlass transition
Method for preserving tissue including immersing the tissue in a solution having a cryoprotectant concentration of at least 75% by weight, a cooling step where the tissue is cooled to a temperature between the glass transition temperature of the solution having a cryoprotectant concentration of at least 75% by weight and −20° C., a storage step where the tissue is stored at a temperature between the glass transition temperature of the solution and −20° C., a rewarming step, where the tissue is warmed, and a washing step.
Owner:LIFELINE SCI
Allergen-specific induced tolerogenic dendritic cells for allergy therapy
InactiveUS20130058976A1Lower immune responsePeptide/protein ingredientsAntipyreticDendritic cellAllergy treatments
Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.
Owner:SELECTA BIOSCI
Toll like receptor modulators
ActiveUS20090053148A1Prevent diseaseLower immune responseSenses disorderNervous disorderInflammatory Bowel DiseasesAutoimmune responses
The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
Owner:IDERA PHARMA INC
Process for delivering nucleic acids to cardiac tissue
InactiveUS6867196B1High level of expressionHigh pressureBiocideCarbohydrate active ingredientsRNATissue cell
A process for delivering a nucleic acid to a cardiac tissue cell in a mammal is described, comprising introducing a composition consisting of a nucleic acid to a blood vessel, which subsequently delivers the nucleic acid to the cardiac tissue cell. The nucleic acid can be DNA or RNA or plasmid DNA or viral. This process is for purposes of gene therapy, and research.
Owner:WISCONSIN ALUMNI RES FOUND +1
Modified polypeptide
InactiveUS6461849B1Lower immune responseRetain activityMilk preparationOrganic detergent compounding agentsVaccine ImmunogenicityAmino acid residue
The present invention relates to polypeptides with reduced immune response including reduced allergenicity having one or more amino acid residues being substituted with other amino acid residues and / or having coupled one or more polymeric molecules in the vicinity of the polypeptides metal binding site, a method for preparing modified polypeptides of the invention, the use of the polypeptide for reducing the immunogenicity and allergenicity and compositions comprising the polypeptide.
Owner:NOVOZYMES AS
Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine
InactiveCN1381512AExtension of timeHigh selectivityHeavy metal active ingredientsPeptide/protein ingredientsSolubilityHalf-life
A multi-arm tree fork type polyethanediol with active terminal group is disclosed, and can be used to modify the low-molecular medicines, and protein or polypeptide medicines for improving their solubility, stability and immunogenicity, resulting in elongated half life period and raised curative effect.
Owner:PEGBIO
11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions
The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v / v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.
Owner:BIOVIE INC +1
Genes of an otitis media isolate of haemophilus influenzae
InactiveUS20050221439A1Good linkageEasy to modifyAntibacterial agentsSenses disorderStainingMiddle ear
The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and / or the nasopharynx.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA +1
Genes of an otitis media isolate of nontypeable Haemophilus influenzae
InactiveUS8283114B2Good linkageEasy to modifyAntibacterial agentsSenses disorderBiotechnologyHaemophilus
The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and / or the nasopharynx.
Owner:NATIONWIDE CHILDRENS HOSPITAL +1
Polypeptide encoded by a nucleotide sequence of a nontypeable strain of Haemophilus influenzae genome
InactiveUS7241867B2Good linkageEasy to modifyAntibacterial agentsSenses disorderNucleotideHaemophilus influenzae
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA +1
Glycotargeting therapeutics
ActiveUS20170007708A1Reduce immune responseReduce symptomPolypeptide with localisation/targeting motifPeptide/protein ingredientsAutoimmune diseaseTolerability
Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
InactiveUS7491388B1Inhibitory responseReduce rejectionBiocideMammal material medical ingredientsAntigenCells fibroblast
Disclosed is a method of inducing a reduced immune response to a transplant in a recipient by treating said recipient with an amount of fibroblasts or a supernatant from a fibroblast culture effective to reduce or inhibit host rejection of the transplant. The fibroblasts or a supernatant from a fibroblast culture can be administered before, at the same time as, or after the transplant. This method is effective in reducing an immune response to a transplant without compromising the immune response to other foreign antigens. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease.
Owner:MESOBLAST INT
Method to reduce inflammatory response in transplanted tissue
InactiveUS7427606B2Lower immune responseGood effectBiocideSugar derivativesResistant bacteriaAntibiotic Agents
The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com